![Artur Machlenkin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Artur Machlenkin
Directeur Technique/Scientifique/R&D chez
PLURI INC.
Profil
Artur Machlenkin is currently Chief Scientific Officer at Pluri, Inc. since 2023.
Formerly, Dr. Machlenkin was Chief Executive Officer at Pantheon Biosciences Ltd. from 2017 to 2021 and held the position of Head-Immuno Oncology at Compugen USA, Inc. Education includes a doctorate from the Weizmann Institute of Science.
Postes actifs de Artur Machlenkin
| Sociétés | Poste | Début |
|---|---|---|
| PLURI INC. | Directeur Technique/Scientifique/R&D | 01/05/2022 |
Anciens postes connus de Artur Machlenkin
| Sociétés | Poste | Fin |
|---|---|---|
Pantheon Biosciences Ltd.
 Pantheon Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Develops molecular therapies and tools | Directeur Général | 01/09/2021 |
Compugen Usa, Inc.
 Compugen Usa, Inc. The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies. | Corporate Officer/Principal | - |
Formation de Artur Machlenkin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
8
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Pluri, Inc.
 Pluri, Inc. BiotechnologyHealth Technology Develops placenta-based cell therapy products for the treatment of muscle trauma and hematological disorders, radiation damage and inflammation | Health Technology |
Weizmann Institute of Science
 Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Compugen Usa, Inc.
Compugen Usa, Inc. The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies. | |
Pantheon Biosciences Ltd.
Pantheon Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Develops molecular therapies and tools | Commercial Services |
